Krsnaa Diagnostics slumps 4% as Q3 net profit falls, margins shrink

While net profit and EBITDA margin declined on year, revenue rose 34% in Q3.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Shares of Krsnaa Diagnostics slumped 4 percent in early trade on February 13 after the company reported a decline in its Q3 net profit along with a margin contraction.

The company's net profit for the December quarter fell 4.4 percent on-year to Rs 13 crore because of expenses incurred for implementation of two projects across geographies aggregating to Rs 6.1 crore.

The increased expenses also weighed on the company's operational performance as EBITDA margin contracted to 24 percent in Q3 as against 25 percent a year ago. Its revenue, however, grew 34 percent from the year ago period to Rs 158.3 crore.

At 10.09am, shares of Krsnaa Diagnostics were trading at Rs 681.95 on the NSE.

Follow our market blog to catch all the live action

The company was also short-listed to provide 17 MRI and 17 CT scan services in Maharashtra in Q3. The quarter gone by also saw the company being chosen to provide MRI services in five Madhya Pradesh districts. It also bagged a contract to provide HPLC tests in 21 districts of Maharashtra.

The company also expanded its presence by setting up 195 centres across the country. The company's new pathology project was also operationalised in Assam during the quarter.

"These recent contract wins underscore the exceptional capabilities of our in-house teams, reflecting their proficiency in navigating the intricate bidding process, meeting all necessary requirements and ultimately securing these contracts," Managing Director Pallavi Bhatevara said.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.